Inhalable Carbonyl Sulfide Donor-Hybridized Selective Phosphodiesterase 10A Inhibitor for Treating Idiopathic Pulmonary Fibrosis by Inhibiting Tumor Growth Factor-β Signaling and Activating the cAMP/Protein Kinase A/cAMP Response Element-Binding Protein (CREB)/p53 Axis

Quan Wang, Xinyue Liu, Yuan Han, Fengcai Zhang, Jiafei Wu, Dongjing Yang, Qian Jiang, Yi‐You Huang, Guihong Chai, Hai‐Bin Luo, Lei GuoACS 2024 · DOI

Abstract

Idiopathic pulmonary fibrosis (IPF) is a debilitating, incurable, and life-threatening disease that lacks effective therapy. The overexpression of phosphodiesterase 10A (PDE10A) plays a vital role in pulmonary fibrosis (PF). However, the impact of selective PDE10A inhibitors on the tumor growth factor-β (TGF-β)/small mother against decapentaplegic (Smad) signaling pathway remains unclear. Herein, we have exploited a novel carbonyl sulfide (COS)/hydrogen sulfide (H<sub>2</sub>S)-donor hybrid PDE10A inhibitor called <b>COS-2080</b> with a well-defined mechanism of H<sub>2</sub>S-releasing action. It exhibited highly potent inhibitory activity against PDE10A and excellent PDE subfamily selectivity. Moreover, <b>COS-2080</b> demonstrated significant antifibrotic effects by inhibiting cell proliferation and mitigating fibroblast-to-myofibroblast transition (FMT). A dry powder inhalation formulation called <b>COS-2080-DPI</b> has been developed using the ultrasonic spray freeze drying (USFD) technique, demonstrating significant antifibrotic efficacy in mice with bleomycin-induced PF at a dosage approximately 600 times lower than pirfenidone. This remarkable antifibrotic efficacy of <b>COS-2080</b> on TGF-β1-induced FMT could be primarily attributed to its inhibition of the Smad2/Smad3 phosphorylation. Moreover, <b>COS-2080</b> effectively attenuated fibrosis in MRC-5 cells by activating the cAMP/protein kinase A (PKA)/CREB pathway and potentially increasing levels of p53 protein. Our findings suggest that effective inhibition of PDE10A potentially confers a protective effect on FMT in PF by impeding TGF-β signaling and activating the cAMP/PKA/CREB/p53 axis.
BibTeX
@inproceedings{wang2024inhalable,
  author = {Quan Wang and Xinyue Liu and Yuan Han and Fengcai Zhang and Jiafei Wu and Dongjing Yang and Qian Jiang and Yi‐You Huang and Guihong Chai and Hai‐Bin Luo and Lei Guo},
  title = {{Inhalable Carbonyl Sulfide Donor-Hybridized Selective Phosphodiesterase 10A Inhibitor for Treating Idiopathic Pulmonary Fibrosis by Inhibiting Tumor Growth Factor-β Signaling and Activating the cAMP/Protein Kinase A/cAMP Response Element-Binding Protein (CREB)/p53 Axis}},
  booktitle = {ACS},
  year = {2024},
  doi = {10.1021/acsptsci.4c00671},
}

Loading related content...

Figure